Research programme: atypical antipsychotics - SepracorAlternative Names: SEP-226929
Latest Information Update: 26 Mar 2008
At a glance
- Originator Sepracor
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 27 Jun 2006 Preclinical trials in Psychotic disorders in USA (unspecified route)